503470-27-7

Basic information

• Product Name: Benzoic acid, 4-(aminomethyl)-3-methyl-, methyl ester
• CAS NO: 503470-27-7
• Molecular Formula: C10H13NO2
• Molecular Weight: 179.219
• Mol File: 503470-27-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(aminomethyl)-3-methyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(aminomethyl)-3-methyl-, methyl ester(503470-27-7)
• EPA Substance Registry System: Benzoic acid, 4-(aminomethyl)-3-methyl-, methyl ester(503470-27-7)

Safety Data

• Hazardous Substances Data: 503470-27-7(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 619-04-5 3,4-dimethylbenzoic acid 
• 201230-82-2 carbon monoxide 
• 67832-11-5 4-bromo-2-methylbenzonitrile 
• 25978-68-1 methyl 4-cyano-3-methylbenzoate 

Downstream Products

• 877858-15-6 4-(tert-butoxycarbonylamino-methyl)-3-methyl-benzoic acid methyl ester 

Relevant articles and documents

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis. It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacological therapy to date. Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy. In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clinical trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies. To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity. Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency. Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.

VASOPRESSIN V1A ANTAGONISTS

The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V 1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.